1,030
Participants
Start Date
December 29, 2011
Primary Completion Date
April 30, 2024
Study Completion Date
April 30, 2024
Rituximab
375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
Lenalidomide
20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3\~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles
Rituximab-CHOP
7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
Rituximab-CVP
7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
Rituximab-Bendamustine
7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
Local Institution - 52403, New York
Local Institution - 50203, New York
Local Institution - 53603, Westminster
Local Institution - 53303, Richmond
Local Institution - 51703, Orlando
Local Institution - 53803, St. Petersburg
Local Institution - 52503, Englewood
Local Institution - 51303, Nashville
Local Institution - 52203, Lexington
Local Institution - 53003, Southfield
Local Institution - 50803, Chicago
Local Institution - 51003, St Louis
Local Institution - 51203, Dallas
Local Institution - 51103, Houston
Local Institution - 54003, Lubbock
Local Institution - 51603, Colorado Springs
Local Institution - 54103, Chandler
Local Institution - 52003, Los Angeles
Local Institution - 51803, Fullerton
Local Institution - 52703, Seattle
Local Institution - 40222, Koto-ku
Local Institution - 40422, Hiroshima
Local Institution - 50403, Boston
Local Institution - 50503, Boston
Local Institution - 54403, Cherry Hill
Local Institution - 53703, Hackensack
Local Institution - 50903, Morristown
Local Institution - 54303, Sparta
Local Institution - 40722, Chuo-ku
Local Institution - 41122, Minato-ku
Local Institution - 40922, Fukuoka
Local Institution - 40122, Isehara City, Kanagawa
Local Institution - 40322, Kobe
Local Institution - 40622, Kyoto
Local Institution - 41022, Sendai
Local Institution - 40522, Shizuoka
Lead Sponsor
The Lymphoma Academic Research Organisation
OTHER
Celgene
INDUSTRY